Inhibition of indoleamine 2,3-dioxygenase enhances the T-cell response to influenza virus infection

Julie M. Fox,1 Leo K. Sage,1 Lei Huang,3 James Barber,1 Kimberly D. Klonowski,2 Andrew L. Mellor,3 S. Mark Tompkins1 and Ralph A. Tripp1

1Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA
2Department of Cellular Biology, University of Georgia, Athens, GA 30602, USA
3Immunotherapy Center and Department of Medicine, Georgia Regents University, Augusta, GA 30912, USA

Influenza infection induces an increase in the level of indoleamine 2,3-dioxygenase (IDO) activity in the lung parenchyma. IDO is the first and rate-limiting step in the kynurenine pathway where tryptophan is reduced to kynurenine and other metabolites. The depletion of tryptophan, and production of associated metabolites, attenuates the immune response to infection. The impact of IDO on the primary immune response to influenza virus infection was determined using the IDO inhibitor 1-methyl-D,L-tryptophan (1MT). C57BL/6 mice treated with 1MT and infected with A/HKx31 influenza virus had increased numbers of activated and functional CD4+ T-cells, influenza-specific CD8+ T-cells and effector memory cells in the lung. Inhibition of IDO increased the Th1 response in CD4+ T-cells as well as enhanced the Th17 response. These studies show that inhibition of IDO engenders a more robust T-cell response to influenza virus, and suggests an approach for enhancing the immune response to influenza vaccination by facilitating increased influenza-specific T-cell response.

INTRODUCTION

Influenza virus is a worldwide health concern, particularly for persons at the extremes of age, i.e. the young and elderly (Fiore et al., 2010). While protection from influenza virus is mediated by a neutralizing antibody response (Bridges et al., 2008), a potent T-cell response is required for elimination of virally infected cells and protection from heterologous virus infection as T-cells recognize conserved viral epitopes (Doherty et al., 1997). Numerous studies have shown the importance of T-cell memory in protection from disease in mice (Taylor & Askonas, 1986; Thomas et al., 2006). Although the significance of the T-cell response is less understood for humans, there are studies showing that influenza infection is associated with increased frequencies of memory influenza-specific CD8+ T-cells in the lungs compared with the circulating CD8+ T-cells (de Bree et al., 2005; Oshansky & Thomas, 2012), and evidence that memory CD4+ T-cells can reduce disease severity (Wilkinson et al., 2012). Recently, several studies have focused on developing vaccines to elicit potent T-cell responses in an attempt to bypass the need for yearly vaccination by providing cross-protective immunity (Guillonneau et al., 2009; Mueller et al., 2010).

Several studies have addressed mechanisms that may facilitate the host response to immunity, and have shown that inhibition of indoleamine 2,3-dioxygenase (IDO) has the potential to increase host responses (Dai & Dai, 2008; Liu et al., 2007). IDO is an intracellular enzyme in the kynurenine pathway that catalyzes tryptophan into kynurenine (Grohmann et al., 2003) and was initially shown to provide protection from fetal rejection mediated through T-cells (Munn et al., 1998). This protection was attributed to reduction in tryptophan levels causing immune cells to arrest in the cell cycle and T-cells to become anergic (Fallarino et al., 2006; Munn et al., 2005). Furthermore, IDO activity has been shown to skew CD4+ T-cells toward a Treg phenotype over a proinflammatory response (Baban et al., 2009). IDO activity is linked to immune attenuation and maintaining an immunosuppressive environment; therefore inhibition of IDO has the potential to reverse these effects as seen in the alloantigen memory T-cell response (Grohmann et al., 2003; Terness et al., 2002). Several studies have focused on the role of IDO in the maintenance of cancerous cells and tumours and resistance to T-cell cytotoxicity (Sharma et al., 2007; Wainwright et al., 2012). In some studies, inhibition of IDO using 1-methyl-tryptophan (1MT) was able to reduce the size and growth of tumours, but was unable to provide complete tumour elimination alone (Uyttenhove et al., 2003; Yang et al., 2010).
IDO expression is upregulated through IFN-γ signalling (Bianchi et al., 1988), suggesting IDO may modulate the immune response to viral infection. During influenza virus infection in mice, IDO activity has been shown to increase over time with peak activity coinciding with the peak number of T-cells within the respiratory tract (Yoshida et al., 1979). Thus, while coordinate expression of IDO may serve to regulate the duration of immunity by modulating the T-cell response, it is also likely that IDO-mediated immune attenuation may hinder the quantity and/or quality of the T-cell response. Recent studies have shown IDO to have an attenuating role in the immune response to human immunodeficiency virus (HIV; Andersson et al., 2005), Leishmania major (Makala et al., 2011) and Toxoplasma gondii (Murakami et al., 2012).

IDO inhibition during combined natural killer (NK) T-cell activation and influenza vaccination has been shown to boost protective immunity (Fallarini et al., 2008; Guillonneau et al., 2009); however, it remains unclear how IDO impacts the immune response to influenza virus infection. To address this in this study, 1MT was used to pharmacologically inhibit IDO activity in mice infected with HKx31 (X31). The T-cell response to infection was evaluated in lung airways. The results show that IDO inhibition allowed for an enhanced Th1 response, increased the functional influenza virus-specific CD8\(^{+}\) T-cell response, and produced higher quantities of effector memory cells.

**RESULTS**

**Influenza infection increases IDO activity in the lungs**

The presence of IDO is associated with attenuated T-cell responses to infectious agents (Boasso et al., 2007; Makala et al., 2011). As these pathogens drive expression of IFN-γ, IDO activity is upregulated in dendritic cells, macrophages and epithelial cells (Bianchi et al., 1988; Hwu et al., 2000; Munn et al., 1999). IDO activity has been previously shown to be upregulated in the lungs of influenza-infected mice (Yoshida et al., 1979); however, the effect IDO has on the quantity and quality of the anti-influenza T-cell response has not been examined. In this study, we address the hypothesis that inhibition of IDO activity during T-cell priming will augment the magnitude and duration of the pulmonary T-cell response to influenza virus infection. To test this, IDO expression was inhibited using 1MT, a competitive inhibitor of IDO (Cady & Sono, 1991). 1MT was administered via drinking water 3 days prior to infection, and the mice remained on 1MT throughout the course of the study. IDO activity was measured in mice receiving 1MT or vehicle (sweetened water) by evaluating the ratio of kynurenine (kyn) to tryptophan (trp) in lung homogenates and serum of influenza-infected mice at 0, 2, 4, 6, 8, 10, 12 and 14 days post-infection (p.i.) (Fig. 1). The kyn/trp ratio directly measures IDO activity by comparing the concentrations of metabolite to substrate produced.

The serum kyn/trp ratios in mice receiving 1MT or vehicle control were similar to day 10 p.i.; however, there was a significant (P<0.05) difference in kyn/trp ratios in the serum of control versus 1MT-treated mice on day 12 p.i. (Fig. 1a). Although the kyn/trp ratios were similar to day 10 p.i., there was a trend towards increased kyn/trp ratios in control compared with 1MT-treated mice. In comparison, the kyn/trp ratios were substantially higher in the lungs following influenza infection compared with control-treated mice, suggesting that infection modulates IDO activity (Fig. 1b), and at day 4 p.i., there was a small but significant (P<0.05) difference in IDO activity in the lungs (Fig. 1b). Notably, at day 10 p.i., a significant (P<0.01) increase in the kyn/trp ratios was evident in the lungs of control compared with 1MT-treated mice (Fig. 1b). These findings are consistent with a previous report showing that IDO activity peaks between day 10 and 11 p.i. in the lungs after influenza infection (Yoshida et al., 1979), and also

---

**Fig. 1.** Influenza infection increases IDO activity in the lungs and sera. Mice were treated with 1MT or control 3 days prior to infection. On day 0, i.e. 3 days after treatment, mice were intranasally (i.n.) infected with 10\(^3\) p.f.u. X31 in PBS. (a) Serum and (b) lung homogenates were collected every other day from day 0 (uninfected animals) until day 14 p.i. Each time point represents the mean and SEM of 3–5 mice per group and shows two independent experiments. (**P** value <0.01 and *P* value <0.05).
demonstrates a temporal pharmacological inhibition of influenza-induced IDO activity through the administration of 1MT. Since IDO activity peaked at day 10, we evaluated the cellular response at this time point for the remainder of the study.

**IDO inhibition does not affect leukocyte infiltration or viral clearance**

Since IDO has been shown to increase apoptosis and reduce cell proliferation (Lee *et al.*, 2002; Munn *et al.*, 1999), we sought to determine if IDO affected pulmonary leukocyte numbers. To examine the effects of IDO inhibition on the overall frequency of cells responding to virus infection, the number of leukocytes in the bronchoalveolar lavage (BALs) and draining mediastinal lymph nodes (MLNs) were determined at day 10 p.i. It is known that following influenza virus infection in mice, NK cells can be detected in the airways at day 3 p.i., peaking by day 5 p.i., whereby influenza-specific T-cells begin to accumulate at detectable frequencies in the lung airways at day 5 p.i. with their overall numbers peaking at day 10 p.i. (Culley, 2009; Flynn *et al*., 1998; Kreijtz *et al*., 2011). In this study, 1MT treatment did not have any substantial effect on the overall level or kinetics of pulmonary leukocyte recruitment (Fig. 2a). Similarly, 1MT treatment did not have any substantial effect on MLN cell numbers (Fig. 2b).

It was important to determine if IDO was selectively affecting the frequency and/or function of specific pools of respondent leukocytes, as modulation of local tryptophan levels has been shown to affect the survival and function of T-cells (Fallarino *et al*., 2002). Examination of the CD4⁺ and CD8⁺ T-cell subpopulations isolated from the BALs of 1MT-treated mice showed no significant difference as compared with vehicle treated mice (Fig. 1c), while there was an increase in the CD4⁺ T-cell population in the MLNs in the control-treated mice (Fig. 1d).

Previous studies have shown that inhibition of IDO reduces the pathogen load during *Leishmania* infections (Makala *et al*., 2011). Thus, we wanted to determine if 1MT treatment had any effect on lung virus clearance. No differences in virus were evident between 1MT- and control-treated mice by TCID₅₀ (Fig. S1a, available in online support).
JGV Online) or M gene expression (Fig. S1b). As differences in IDO activity were not detected until day 10 p.i. in lung homogenate (Fig. 1a), and there was no substantial difference in pulmonary CD8^+ T-cell numbers (Fig. 2c), it is not surprising that 1MT had no detectable effect on virus clearance.

**Inhibition of IDO activity enhances the Th1 cytokine response**

The CD4^+ T-cell response to influenza infection in mice has been characterized as a Th1-type response (Cella et al., 2000; Doherty et al., 1997); however, IDO has been shown to activate regulatory T-cells and block their conversion into...
Th17-like cells (Baban et al., 2009). Thus, the effects of IDO on the differentiation of Th1- or Th2-type CD4+ T-cells were determined in the BALs. Cytokines representative of Th1-, Th2- and Th17-type responses were determined, i.e. IFN-γ, IL-4 and IL-6, respectively. The proportion and frequency of CD4+ T-cells expressing IFN-γ, IL-6 or IL-4 was determined at day 10 p.i. (Fig. 3). There was a significant increase (P<0.05) in the percentage (Fig. 3b) and number (Fig. 3c) of CD4+ T-cells expressing IFN-γ. There was also a significant increase in the percentage of CD4+ T-cells expressing IL-6 (Fig. 3d), although there was only a slight increase in the number of CD4+ T-cells expressing IL-6 (Fig. 3e). There was no change in the CD4+ IL-4-expressing population (Fig. 3f, g), showing a specific role of IDO in the suppression of a Th1/Th17 response. Together, these findings indicate that IDO inhibition through 1MT treatment enhances the Th1-type response indicated by higher numbers of BAL CD4+ T-cells expressing IFN-γ following infection with influenza virus.

**IDO inhibition is associated with increased numbers of influenza-specific CD8+ T-cells**

Total numbers of CD8+ T-cells in the BALs of 1MT-treated mice were not affected (Fig. 2c); thus virus-specific CD8+ T-cell frequencies were determined following 1MT or vehicle treatment. CD8+ T-cells from the BALs were collected at day 10 p.i. and stained with tetramers detecting reactivity to the influenza nucleoprotein (NP) (H-2D^bNP366–374), acid polymerase (PA) (H-2D^bPA224–233) or basic polymerase 1 (PB1) (H-2K^bPB1703–711) (Fig. 4). NP and PA have been shown to be the dominant influenza-specific epitope (Fig. 4b). There were no changes in the CD8+ T-cell population in the BALs of 1MT-treated mice (Fig. 4a), treatment with 1MT increased the number of CD8+ T-cells expressing IFN-γ (Fig. 4b) and there was an overall trend toward higher numbers of NP- and PA-specific CD8+ T-cells (Fig. 4b). There were no substantial differences in the frequency of influenza-specific CD8+ T-cells in the MLNs of 1MT- and control-treated groups (data not shown), suggesting that this increase occurs at the site of infection. Since IDO has a role in dampening the T-cell response, and there were increases in the number of influenza-specific CD8+ T-cells in the BALs, the T-cell receptor (TCR) Vβ diversity was examined in 1MT-treated and control mice at days 0, 6, 8, 10, 12 and 14 p.i. Splenocytes were stained for TCR Vβ 2, 6, 7, 8 and 8.1/8.2. No substantial variation was detected in TCR Vβ usage among influenza-specific CD8+ T-cells from that previously shown (La Gruta et al., 2006) (data not shown). These results support the finding that IDO inhibition increased the numbers of pulmonary CD8+ T-cells that are influenza virus-specific.

**IDO affects influenza-specific CD8+ T-cell functionality and the effector memory population**

As IDO treatment was associated with an enhanced Th1-type response determined by increased numbers of CD4+ T-cells expressing IFN-γ (Fig. 3b), and there were increases in the number of PA-specific CD8+ T-cells in the BALs (Fig. 4b), the effect of IDO inhibition on CD8+ T-cell activation was evaluated. To determine if IDO inhibition was linked to a concomitant increase in virus-specific CD8+ T-cells, the percentage and number of CD8+ T-cells and influenza-specific CD8+ T-cells expressing IFN-γ collected from the BALs was analysed 10 days p.i. (Fig. 5a, c, d). In contrast to the increased numbers of CD4+ T-cells expressing IFN-γ in the BALs of 1MT-treated mice...
Con 39.5% 41.5%

(a) Con 1MT

(b) Con 1MT

NP 366 PA 224 PB1 703

(c) CD8+IFN-γ

(d) CD8+IFN-γ

(e) Influenza-specific CD8+ IFN-γ+T-cells

(f) Influenza-specific CD8+ IFN-γ+T-cells

1MT Con 1MT Con 1MT Con

Treatment

Percentage of CD3+CD8+ cells

Cell number

J. M. Fox and others

Journal of General Virology 94

Downloaded from www.microbiologyresearch.org by
IP: 54.70.40.11
On: Thu, 13 Jun 2019 00:37:29
Fig. 5. IDO inhibition increases the frequency of functional PA-specific CD8+ T-cells. Mice were treated with 1MT or control, as described, and infected with 10^3 p.f.u. X31 i.n. Ten days p.i., single cells from the BALs were stimulated for 4 h with influenza immunodominant peptides and subsequently stained for intracellular expression of IFN-γ. (a, b) Representative dot plots of (a) CD8+ T-cells and (b) influenza-specific CD8+ T-cells expressing IFN-γ. (c) Percentage and (d) frequency of CD8+ T-cells expressing IFN-γ. (e) Percentage and (f) frequency of influenza-specific CD8+ T-cells expressing IFN-γ. Representative data from one experiment are shown from three independent experiments. (*P value <0.05).

(Fig. 3), inhibition of IDO did not change the percentage of CD8+ T-cells expressing IFN-γ (Fig. 5c, d). There were slightly higher numbers of BAL CD8+ T-cells expressing IFN-γ in 1MT-treated mice compared with control mice (Fig. 5d). CD8+ T-cells were stained with H-2D^B NP366-374, H-2D^B PA224-233 and H-2K^B PB1703-711 tetramers and for intracellular IFN-γ to evaluate activation (Fig. 5b, e, f). Of the CD8+ T-cells expressing IFN-γ, there was a significant (P<0.05) increase in the number of PA-specific T-cells, while NP and PB1 CD8+ T-cells showed no difference between the treatments (Fig. 5f). These findings indicate that in the absence of IDO, the activated PA-specific CD8+ T-cells are increased over the NP and PB1. These results suggest that IDO modifies the CD8+ T-cell frequency, and IDO inhibition increases the number of functional influenza virus-specific CD8+ T-cells, in particular a co-dominant epitope, at the site of infection.

Given the increase in CD4+ and CD8+ T-cell activity with IDO inhibition, the level of effector and central memory T-cell populations were evaluated. CD4+ and CD8+ T-cells were phenotyped for expression of CD44 and CD62L, with CD44^hiCD62L^lo expression being indicative of effector memory cells and CD44^hiCD62L^hi expression representing central memory cells (Roberts et al., 2005). Ten days post-infection there was an increased frequency of CD8+ effector

Fig. 6. Inhibition of IDO activity increases the presence of CD8+ effector memory cells. Mice were treated with 1MT or control 3 days prior to infection. On day 0, mice were i.n. infected with 10^3 p.f.u. X31. (a, b) CD8+ and (c, d) CD4+ T-cells collected 10 days p.i. from the BALs were stained for the presence of CD44 and CD62L. Representative data from one experiment is shown from two independent experiments. (*P value <0.05).
memory cells in the absence of IDO activity (Fig. 6a, b). While there was no difference between the CD4+ T-cell effector memory populations (Fig. 6c, d), there was a significant increase in the central memory population in control compared with 1MT-treated mice (Fig. 6d). These results support a role of IDO in the reduction of the production of the effector memory population, particularly the CD8+ T-cell population.

**DISCUSSION**

The findings from this study show that IDO has an immune dampening role in the response to influenza virus infection where IDO inhibition resulted in an overall enhancement in the number of activated T-cells in the lungs. IDO dampening of the IFN-γ response appeared greatest for the CD4+ T-cell compartment with an enhanced Th1 and Th17 response, although IFN-γ expression by CD8+ T-cells was also affected. In the BALs, the most abundant functional CD8+ T-cell response in the absence of IDO was directed to the PA epitope (PA224–233) compared with the control-treated mice. These findings suggest that IDO might alter CD8+ T-cell frequency while there is no detectable shift in the TCR Vβ usage of the CD8+ T-cells. This could possibly be attributed to enhanced trafficking of PA-specific T-cells to the lungs related to a survival advantage.

Changes in the frequency have implications on the diversity of the T-cell population directed at influenza. There are multiple possibilities of how IDO affects the influenza-specific CD8+ T-cell population. One potential mechanism is through changes in antigen expression in antigen presenting cells (APCs). NP is commonly expressed by most APCs including dendritic cells and non-dendritic cells, while the PA peptide is almost exclusively expressed on dendritic cells and this has been shown to affect the peptide dominance between acute and secondary influenza infection (Crowe et al., 2003). The expression pattern for PB1, however, has not been established. Since both macrophages and dendritic cells can express IDO through stimulation with IFN-γ (Hwu et al., 2000), there is potential for a differential expression pattern of influenza epitopes. This could be driven through the immunoproteasome, which is also upregulated through IFN-γ (Tanoka & Kasahara, 1998). The immunoproteasome is responsible for the cleavage of proteins during infection for peptide presentation through the MHC class I pathway (Kloetzel, 2001) and IDO may be influencing the expression of epitopes. Furthermore, it has been shown that immunodominance is affected by the recruitment and expansion of CD8+ T-cells (La Gruta et al., 2010). With reduced IDO activity, there was increased activation of the influenza-specific CD8+ T-cells, suggesting prolonged exposure to antigen or continued activation of T-cell arriving ‘late’ to the immune response. The continued activation can be due in part to the reduced production of Treg cells as a result of IDO inhibition (Baban et al., 2009).

Although inhibition of IDO increased the amount of virus-specific cells expressing IFN-γ, surprisingly 1MT treatment did not affect lung viral titres as noted for other pathogens (Makala et al., 2011). One explanation may relate to the tempo of IDO expression. Accordingly, there are likely two phases of IDO activity in response to influenza virus infection, the first during initial infection of respiratory epithelial cells, followed by a larger induction related to IFN-γ produced by CD4+ and CD8+ T-cells. IFN-γ is an extremely potent activator of IDO (Bianchi et al., 1988), and the second wave of IDO activity is more robust and can be easily detected by examination of kyn levels or the ratio of kyn/trp. As the first induction of IDO likely occurs during infection of respiratory epithelial cells, this lower level of IDO activity has limited effects on the early response to infection, and thus no immediate impact on virus clearance. Another possibility may be linked to the location of T-cell activation. Findings from our lab show IDO to be active in the MLNs of influenza-infected mice. It is possible that the T-cell response is affected by the expression of IDO in the lymph node, rather than in the lungs, which would help explain the lack of differences in viral titres. Furthermore, influenza infection of epithelial cells induces IDO (Jacoby & Choi, 1994); however, the role of IDO in lung epithelial cells has not been thoroughly examined. IDO may be involved in cell survival, as it does have antioxidant properties which could reduce the damage caused by superoxides produced during infection (Hirata & Hayashi, 1975). In addition, increased tryptophan availability has been shown to aid in pathogen proliferation (Gupta et al., 1994), and this may also facilitate influenza replication.

Interestingly, there was no difference in the level of serum IgG titres between 1MT-treated and control mice (data not shown), and the immunoglobulin isotype was the same between the two groups (data not shown). These findings suggest that IDO has no detectable effect on the B cell response to infection. This is consistent with an earlier study that showed IDO treatment of peripheral blood-derived B-cells had no effect on B-cells or their proliferation (Frumento et al., 2002). Furthermore, treatment with 1MT did not change the expression of IFN-γ from splenocytes 21 days p.i. by ELISPOT detection following influenza peptide stimulation compared with control-treated mice (data not shown). Since there was an increase in the CD8+ T-cell effector memory population, the effect in the memory population may be more evident in the resident lung cells (not evaluated in this study).

In this study, increased IDO activity was induced following influenza virus infection, a feature that had a dampening effect on the immune response. Specifically, 1MT-treated mice had higher numbers of Th1-CD4+ T-cells and effector memory CD8+ T-cells. IDO activity peaked in the lungs at day 10 p.i., a finding consistent with an earlier study (Yoshida et al., 1979). Early leukocyte recruitment to the lungs was not substantially affected by IDO inhibition (data not shown). There are several possibilities for this...
that relate to trp catabolism, particularly in the MLNs. IDO metabolites have been shown to induce apoptosis of T-cells (Hayashi et al., 2007) and to sway the CD4+ T-cells to a regulatory phenotype (Favre et al., 2010). The production of regulatory T-cells in the MLNs could suppress the pulmonary T-cell recruitment. Preliminary work in our lab shows that 1MT treatment decreases the number of cytotoxic Treg cells in the BALs. The lack of Treg suppression and production of trp metabolites may contribute to altered leukocyte trafficking, proliferation and increased survival of cells in the airways. Another possibility that is related to Treg production is the inability of inhibitory molecules to produce an effect on the system. The PD-1/PD-L pathway has been linked to IDO expression and activity (Baban et al., 2011). Tregs activated by IDO upregulate the expression of PD-L1/PD-L2 on dendritic cells (Sharma et al., 2007). The lack of PD-L expression will increase the activation and survival of the effector T-cell population (Brown et al., 2003).

The results from this study show that regulating IDO can enhance aspects of the adaptive immune response to influenza infection. This is attractive as regulating IDO activity during vaccination may facilitate vaccine efficacy. These observations support the concept that controlling IDO activity during vaccination with the live, attenuated influenza virus may be a means to augment vaccine efficacy and the robustness of the T-cell response, an attribute that could potentially facilitate heterosubtypic immunity.

**METHODS**

**Mice, virus propagation and infection.** Female C57BL/6 mice (6–8 weeks old) were purchased from Charles River Laboratories (Raleigh, NC) and all animal studies were approved by the Animal Care and Use Committee of the University of Georgia. A/HKx31 (X31, H3N2) influenza virus was propagated in the allantoic cavity of 9-day-old embryonated chicken eggs at 37 °C for 72 h. Titres were determined by an influenza plaque assay (Matrosovich et al., 2006). All mice were anaesthetized by intraperitoneal injection of Avertin (2,2,2-tribromoethanol) followed by intranasal infection with 10^5 p.f.u. X31 in 50 μl PBS at 8–10 weeks old.

**Preparation and administration of 1-methyl-DL-tryptophan (1MT).** The d,l racemic mixture of 1MT (Sigma-Aldrich) was administered to the mice through drinking water at a concentration of 2 mg ml⁻¹. The treated water was prepared by dissolving 1MT powder in water using NaOH. The pH was adjusted to 7. To coax the mice to drink the water, aspartame was added to the water. The water was filter-sterilized and contained in autoclaved water bottles covered in aluminium foil. Control animals received aspartame-sweetened water only. 1MT-treated water was given to the mice 3 days prior to infection and the animals remained on the treatment throughout the course of the infection. Mice receiving the 1MT treatment were weighed during the 3 days prior to infection to ensure consumption of the water. The water and water bottles were changed every 5–7 days until processing. The concentration of kyn and trp was determined by HPLC analysis using a standard curve (Laich et al., 2002). Briefly, proteins were removed from the clarified lung homogenate and serum using trichloroacetic acid and analysed using a C18 reverse phase column (Restek).

**Isolation and phenotyping of lymphocyte populations.** At 10 days p.i., mice were anaesthetized and BALs were collected by instillation of 1 ml PBS into the lungs three times for each mouse. MLNs were removed and placed into HBSS at 4 °C until processing. Single-cell suspensions were prepared from the MLNs using a 100 μm cell strainer (BD Biosciences). Cells were centrifuged and resuspended in complete tumour medium (CTM) prepared as previously described (Zhang et al., 2000) in RPMI-1640 (HyClone). Cell numbers were determined with a Coulter Counter (Beckman Coulter). Single cell suspensions were plated between 5 × 10⁶ to 5 × 10⁷ cells per well. The cells were resuspended in staining wash buffer (SBW) (PBS + 1 % BSA + 0.09 % NaNO₂) followed by incubation with Fc Block (BD Pharmingen) at 4 °C for 15 min. Cells were then incubated with anti-CD3e (clone 145-2C11), anti-CD8α (clone 53-6.7), anti-CD4 (clone RM4-5), anti-CD44 (clone IM7) and anti-CD62L (clone MEL-14) (BD Pharmingen) for 30 min at 4 °C. The cells were rinsed with SBW and fixed with 1 % paraformaldehyde in PBS.

For intracellular cytokine staining, cells were stimulated with a cocktail of influenza immunodominant peptides (NP 366–374, PA 224–233, PB1 700–711) (1 μg ml⁻¹), irrelevant peptide (RSV M242,903 (1 μg ml⁻¹) or DMSO for 4 h in CTM at 37 °C followed by surface staining with anti-CD3, anti-CD8α, H2DNP366–374 tetramer, H2DβPA224–233 tetramer or H2KβPB1 700–711 tetramer (NIH Tetramer Core Facility, Emory, Atlanta, GA) for 1 h at room temperature for the IFN-γ response from CD8⁺ T-cells. Cells were stimulated with UV-inactivated X31 virus (1:100) or allantoic fluid for 6 h in CTM at 37 °C followed by surface staining with anti-CD3 and anti-CD4 for intracellular staining of CD4⁺ T-cells for IFN-γ (clone XMG1.2), IL-6 (clone MP5-32C11) or IL-4 (clone 11B11) (BD Pharmingen). Cultured cells were stained as described above, but were kept in the presence of GolgiStop (BD Biosciences). Following surface staining, cells were rinsed with SBW+GolgiStop and fixed and permeabilized with the Fixp3 fixation/permeabilization solution (eBioscience). The cells were rinsed with Perm/Wash Buffer (BD Biosciences) and incubated with intracellular markers listed above for 30 min at 4 °C. Cells were washed with Perm/Wash Buffer and resuspended in PBS. All samples were run on a LSRII Flow cytometer (BD Biosciences) and analysed using BD FACSDiva software or FloJo (Tree Star). All populations were initially gated on CD3⁺ cells. Isotype control antibodies and mock stimulation were used to set gates for analysis.

**Statistical analysis.** Statistics were performed using GraphPad Prism Version 5.01. The data were analysed using a two-tailed Student’s t-test comparing 1MT treatment with control-treated mice at each time point. Significance was assigned when the P value was <0.05.

**ACKNOWLEDGEMENTS**

We thank Dr Phillip Chandler for his technical assistance with 1MT preparation and administration, Spencer Poore and Scott Johnson for assistance with animal work, and the NIH Tetramer Core Facility for generating the tetramers. This work was supported by the National Institutes of Health U01 grant AI083005-01.

**REFERENCES**


Cytokine infection. Toxoplasma gondii macrophage tryptophan catabolism.


